Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Waldenstrom Macroglobulinemia 1Optic Neuritis 1Neuromyelitis Optica 1Myelitis, Transverse 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

fludarabine 2Cyclophosphamide 2ublituximab 1thymoglobulin 1prednylidene 1deltacortene 1carmustine, poliferprosan 20 drug combination 1Sugars 1Rituximab 1Prednisone 1Peripheral Blood Stem Cell Transplantation 1Mitoxantrone 1Melphalan 1LFB-R603 1Immunoglobulins, Intravenous 1Etoposide 1Data Collection 1Cytarabine 1Carmustine 1Antilymphocyte Serum 1Alleles 14-Aminopyridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neuromyelitis Optica × LFB-R603 × Clear all
NCT02276963 2019-06-06

Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses

Johns Hopkins University

Phase 1 Completed
6 enrolled 9 charts

Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡